TrialThe Journal of dermatology2025

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial.

Yukari Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.